Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP7 | Q9UHL4 | 4/20 | 0.58 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.58 |
| ▸ | NOD1 | Q9Y239 | 9/20 | 0.56 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.54 |
| ▸ | MME | P08473 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | GNPAT | O15228 | 1/20 | 0.44 |
| ▸ | DPP4 | P27487 | 2/20 | 0.44 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.44 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.43 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.43 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.43 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29898351 | 1.00 | DPP7 (0.58) | DPP7DPP8NOD1SLC15A1MME | |
| SCHEMBL15757004 | 1.00 | DPP7 (0.58) | DPP7DPP8NOD1SLC15A1MME | |
| SCHEMBL15757005 | 1.00 | DPP7 (0.58) | DPP7DPP8NOD1SLC15A1MME | |
| SCHEMBL8680597 | 0.89 | NOD1 (0.51) | DPP7DPP8NOD1SLC15A1MME | |
| SCHEMBL8680601 | 0.89 | NOD1 (0.51) | DPP7DPP8NOD1SLC15A1MME | |
| SCHEMBL31383723 | 0.89 | DPP8 (0.51) | DPP7DPP8NOD1SLC15A1MME | |
| SCHEMBL29476460 | 0.86 | DPP8 (0.60) | DPP7DPP8NOD1SLC15A1MME | |
| SCHEMBL29674589 | 0.86 | NOD1 (0.56) | DPP7DPP8NOD1GNPATDPP4 | |
| SCHEMBL2850058 | 0.86 | DPP7 (0.58) | DPP7DPP8NOD1SLC15A1DPP4 | |
| SCHEMBL29376792 | 0.86 | DPP7 (0.58) | DPP7DPP8NOD1SLC15A1DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220339239-A1 | USE OF MELANOCORTINS TO TREAT INSULIN SENSITIVITY | IPSEN PHARMA SAS (FR) | 2022-10-27 | — | — | US | claimed |
| EP-4711004-A2 | METHOD OF TREATING MELANOCORTIN-4 RECEPTOR PATHWAY-ASSOCIATED DISORDERS | Rhythm Pharmaceuticals, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| US-20260001915-A1 | METHODS FOR TREATING OBESITY WITH AN MC4R AGONIST | RHYTHM PHARMACEUTICALS INC (US) | 2026-01-01 | — | — | US | disclosed |
| EP-4618952-A2 | METHODS FOR TREATING OBESITY WITH AN MC4R AGONIST | Rhythm Pharmaceuticals, Inc. (US) | 2025-09-24 | — | — | EP | disclosed |
| US-20250195606-A1 | METHOD OF TREATING MELANOCORTIN-4 RECEPTOR PATHWAY-ASSOCIATED DISORDERS | CHARITÉ - UNIVERSITÄTSMEDIZIN BERLIN (DE) | 2025-06-19 | — | — | US | disclosed |
| CN-120152725-A | Methods of treating obesity using MC4R agonists | 节奏制药公司 | 2025-06-13 | — | — | CN | disclosed |
| WO-2025106751-A1 | COMBINATIONS OF A POTASSIUM CHANNEL ACTIVATOR AND AN MC4R AGONIST AND RELATED METHODS OF USE | RHYTHM PHARMACEUTICALS, INC. (US) | 2025-05-22 | — | — | WO | disclosed |
| EP-4554607-A2 | METHODS FOR TREATING OBESITY WITH AN MC4R AGONIST | Rhythm Pharmaceuticals, Inc. (US) | 2025-05-21 | — | — | EP | disclosed |
| US-12263202-B2 | Method of treating melanocortin-4 receptor pathway-associated disorders | RHYTHM PHARMACEUTICALS, INC. (US) | 2025-04-01 | — | — | US | disclosed |
| US-20250082717-A1 | COMPOSITIONS FOR TREATING KIDNEY DISEASE | RHYTHM PHARMACEUTICALS INC (US) | 2025-03-13 | — | — | US | disclosed |
| US-20240182519-A1 | MELANOCORTIN RECEPTOR LIGANDS MODIFIED WITH HYDANTOIN | IPSEN PHARMA S.A.S. (FR) | 2024-06-06 | — | — | US | disclosed |
| WO-2024108198-A2 | METHODS OF TREATING OBESITY WITH AN MC4R AGONIST | RHYTHM PHARMACEUTICALS, INC. (US) | 2024-05-23 | — | — | WO | disclosed |
| US-20240058414-A1 | METHODS OF TREATING MELANOCORTIN-4 RECEPTOR PATHWAY-ASSOCIATED DISORDERS | RHYTHM PHARMACEUTICALS, INC. | 2024-02-22 | — | — | US | disclosed |
| WO-2024015880-A2 | METHODS FOR TREATING OBESITY WITH AN MC4R AGONIST | RHYTHM PHARMACEUTICALS, INC. (US) | 2024-01-18 | — | — | WO | disclosed |
| EP-4216979-A1 | METHODS OF TREATING MELANOCORTIN-4 RECEPTOR PATHWAY-ASSOCIATED DISORDERS | Rhythm Pharmaceuticals, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| CN-116507353-A | Methods of treating melanocortin-4 receptor pathway-related disorders | 节奏制药公司 | 2023-07-28 | — | — | CN | disclosed |
| US-20220339239-A1 | USE OF MELANOCORTINS TO TREAT INSULIN SENSITIVITY | IPSEN PHARMA SAS (FR) | 2022-10-27 | — | — | US | disclosed |
| EP-4029513-A1 | MELANOCORTIN-4 RECEPTOR AGONISTS FOR THE TREATMENT OF DISORDERS CHARACTERISED BY POMC GENE HYPERMETHYLATION | Rhythm Pharmaceuticals, Inc. (US) | 2022-07-20 | — | — | EP | disclosed |
| EP-3988108-A1 | METHOD OF TREATING MELANOCORTIN-4 RECEPTOR-ASSOCIATED DISORDERS IN HETEROZYGOUS CARRIERS | Rhythm Pharmaceuticals, Inc. (US) | 2022-04-27 | — | — | EP | disclosed |
| WO-2022067086-A1 | METHODS OF TREATING MELANOCORTIN-4 RECEPTOR PATHWAY-ASSOCIATED DISORDERS | RHYTHM PHARMACEUTICALS, INC. (US) | 2022-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250082717-A1 | COMPOSITIONS FOR TREATING KIDNEY DISEASE | MC4R, MC2R, MC5R | DPP7 1943/4885DPP8 1989/4885NOD1 4204/4885 |
| US-20240058414-A1 | METHODS OF TREATING MELANOCORTIN-4 RECEPTOR PATHWAY-ASSOCIATED DISORDERS | MC4R, MC5R, MC3R | DPP7 986/4885DPP8 898/4885NOD1 4742/4885 |
| US-12263202-B2 | Method of treating melanocortin-4 receptor pathway-associated disorders | MC4R, MC5R, MC3R | DPP7 2314/4885DPP8 1811/4885NOD1 4879/4885 |
| US-20260001915-A1 | METHODS FOR TREATING OBESITY WITH AN MC4R AGONIST | MC4R, NPY4R, MC3R | DPP7 1818/4885DPP8 1558/4885NOD1 4503/4885 |
| US-20240182519-A1 | MELANOCORTIN RECEPTOR LIGANDS MODIFIED WITH HYDANTOIN | MC4R, MC3R, MC1R | DPP7 250/4885DPP8 189/4885NOD1 675/4885 |
| US-20220339239-A1 | USE OF MELANOCORTINS TO TREAT INSULIN SENSITIVITY | MC4R, MC1R, MC3R | DPP7 228/4885DPP8 264/4885NOD1 4363/4885 |
| US-20250195606-A1 | METHOD OF TREATING MELANOCORTIN-4 RECEPTOR PATHWAY-ASSOCIATED DISORDERS | MC4R, MC5R, MC3R | DPP7 2314/4885DPP8 1811/4885NOD1 4879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.